The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Open accessAbstract
Background: The role of both microglial activation and alpha-synuclein deposition in Parkinson's disease remain unclear. We have tested the hypothesis that if microglia play a primary role in Parkinson's disease pathogenesis, the microglial "activated" phenotype should be associated with histopathological and/or clinical features of the disease. Methods: We have examined microglial MHC class II expression, a widely used marker of microglial activation, the occurrence of CD68-positive phagocytes and alpha-synuclein immunoreactivity in post-mortem human substantia nigra affected by idiopathic Parkinson's disease (PD). Using semi-quantitative severity ratings, we have examined the relationship between microglial activation, alpha-synuclein deposition, classical neuropathological criteria for PD, subtype of the disease and clinical course. Results: While we did not observe an association between microglial MHC class II expression and clinical parameters, we did find a correlation between disease duration and the macrophage marker CD68 which is expressed by phagocytic microglia. In addition, we observed a significant correlation between the degree of MHC class II expression and alpha-synuclein deposition in the substantia nigra in PD. Conclusion: While microglia appeared to respond to alpha-synuclein deposition, MHC class II antigen expression by microglia in the substantia nigra cannot be used as an indicator of clinical PD severity or disease progression. In addition, a contributory or even causative role for microglia in the neuronal loss associated with PD as suggested by some authors seems unlikely. Our data further suggest that an assessment of microglial activation in the aged brain on the basis of immunohistochemistry for MHC class II antigens alone should be done with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dysregulation of microglia functions contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) (6–8), Parkinson’s disease (PD) (9–12) and Huntington’s disease (HD) (13–15).”
From An environment-dependent transcriptional network specifies human microglia identity (2017) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Microglia accumulate near α-synuclein deposits and become proinflammatory in a manner dependent on receptors that also bind Aβ, such as CD36 and TLR263–65.”
From Microglia in neurodegeneration (2018) · cites this paper as [63]
In the citing paper
“Microglia also phagocytose α-synuclein, the constituent protein of Lewy bodies in Parkinson’s and Lewy Body dementias, and become pro-inflammatory in the process, expressing cytokines (IL1β, IL6, TNFα), reactive oxygen species (ROS) and prostaglandin synthesising cyclooxygenase 2 (COX2) [24,25,26].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Self-citationMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Research works printed but not linked: 1
- Graeber MB: Glial inflammation in neurodegenerative diseases. 8th Annual Congress of the British Society for Immunology, Harrogate, 5–8 December 2000, Immunology. 2000, Oxford: Blackwells, Abstract, Supplement
Cited by
Sorted by citations
Items 201–300 of 416
Mok, S. W.-F., Wong, V. K. W., Lo, H. H., Dias, I. R. D. S. R., Leung, E. L., Law, B. Y. K., & Liu, L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107480 · Cited by 39
Jiménez-Ferrer, I., Jewett, M. A. S., Tontanahal, A., Romero‐Ramos, M., & Swanberg, M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.016 · Cited by 37
Neurological effects of glucocerebrosidase gene mutations
Mullin, S., Hughes, D. A., Mehta, A. B., & Schapira, A. H. V. (2018) · European Journal of Neurology · doi:10.1111/ene.13837 · Cited by 39
Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics
Singh, A. K., Tripathi, P., & Singh, S. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00764-w · Cited by 39
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
Jung, Y. J., Tweedie, D., Scerba, M. T., Kim, D. S., Palmas, M. F., Pisanu, A., Carta, A. R., & Greig, N. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656921 · Cited by 37
Microglia in Neurodegenerative Events—An Initiator or a Significant Other?
Harry, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115818 · Cited by 37
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies
Fleming, S. M., Davis, A., & Simons, E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108870 · Cited by 37
The microglial gene regulatory network activated by interferon-gamma
Moran, L. B., Duke, D. C., & Graeber, M. B. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.10.023 · Cited by 37
Self-citationReview: Microglia in protein aggregation disorders: friend or foe?
Gentleman, S. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12017 · Cited by 38
Lecours, C., St‐Pierre, M., Picard, K., Bordeleau, M., Bourque, M., Awogbindin, I. O., Benadjal, A., Ibáñez, F. G., Gagnon, D., Cantin, L., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.044 · Cited by 34
Neuroinflammation is associated with Alzheimer’s disease co-pathology in dementia with Lewy bodies
van Wetering, J., Geut, H., Bol, J. G. J. M., Galis, Y., Timmermans, E., Twisk, J. W. R., Hepp, D. H., Morella, M. L., Pihlstrøm, L., Lemstra, A. W., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01786-z · Cited by 41
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 36
Impact of sex on neuroimmune contributions to Parkinson’s disease
Bourque, M., Morissette, M., Soulet, D., & Paolo, T. D. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110668 · Cited by 36
α‐Synuclein in Parkinson's Disease: From Bench to Bedside
Bellini, G., D’Antongiovanni, V., Palermo, G., Antonioli, L., Fornai, M., Ceravolo, R., Bernardini, N., Derkinderen, P., & Pellegrini, C. (2024) · Medicinal Research Reviews · doi:10.1002/med.22091 · Cited by 42
Zhang, X., Zhu, L.-B., He, J., Zhang, H.-Q., Ji, S., Zhang, C., Hou, N.-N., Huang, C.-P., & Zhu, J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1712-0 · Cited by 34
The degeneration of dopaminergic synapses in Parkinson's disease: A selective animal model
Moráles, I., Sánchez, A., Rodriguez‐Sabate, C., & Rodrı́guez, M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.04.019 · Cited by 35
Walker, D. G., Lue, L.-F., Tang, T. M., Adler, C. H., Caviness, J. N., Sabbagh, M. N., Serrano, G. E., Sue, L. I., & Beach, T. G. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.007 · Cited by 33
Inflammatory Mechanisms in Parkinson’s Disease: From Pathogenesis to Targeted Therapies
Lee, S. Y. H., Yates, N. J., & Tye, S. J. (2021) · The Neuroscientist · doi:10.1177/1073858421992265 · Cited by 34
Characterization of a Parkinson’s disease rat model using an upgraded paraquat exposure paradigm
Cristóvão, A. C., Campos, F. L., Je, G., Esteves, M., Guhathakurta, S., Yang, L., Beal, M. F., Fonseca, B. M., Salgado, A. J., Queiroz, J. A., et al. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14683 · Cited by 33
The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications
Kuter, K. Z., Cenci, M. A., & Carta, A. R. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.02.004 · Cited by 31
More, S. V., Kumar, H., Kim, I., Koppula, S., Kim, B.-W., & Choi, D. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990059 · Cited by 31
Tondo, G., Boccalini, C., Caminiti, S. P., Presotto, L., Filippi, M., Magnani, G., Frisoni, G. B., Iannaccone, S., & Perani, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201351 · Cited by 29
Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?
Ward, R. J., Dexter, D. T., Martín‐Bastida, A., & Crichton, R. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073338 · Cited by 30
Self-citationTrudler, D., Nash, Y., & Frenkel, D. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1399-z · Cited by 31
Dl-3-n-Butylphthalide Exerts Dopaminergic Neuroprotection Through Inhibition of Neuroinflammation
Chen, Y., Wu, T., Li, H., Li, X., Li, Q., Zhu, X., Yu, M., Kuo, S., Huang, F., & Wu, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00044 · Cited by 30
Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases
Han, J., Wang, M., Ren, M., & Lou, H. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1264072 · Cited by 30
Lee, J. A., Son, H. J., Choi, J., Kim, J., Han, S. H., Shin, N., Kim, J. H., Kim, S., Heo, J. Y., Kim, D. J., et al. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.11.006 · Cited by 30
Stoll, A. C., & Sortwell, C. E. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105804 · Cited by 29
Lillethorup, T. P., Glud, A. N., Alstrup, A. K. O., Mikkelsen, T. W., Nielsen, E. N., Zaer, H., Doudet, D. J., Brooks, D. J., Sørensen, J. C. H., Orłowski, D., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.02.005 · Cited by 28
From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein
Heras‐Garvin, A., & Stefanova, N. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.584536 · Cited by 31
Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson’s Disease Risk
Booms, A., & Coetzee, G. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.759571 · Cited by 30
An Overview of Epigenetic Changes in the Parkinson’s Disease Brain
Klokkaris, A., & Migdalska‐Richards, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116168 · Cited by 31
Non-cell-autonomous actions of α-synuclein: Implications in glial synucleinopathies
Lim, S., Kim, H., Kim, D., & Lee, S. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.06.010 · Cited by 28
Nigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms
Backman, E. A., Gardberg, M., Saari, L., Peurla, M., Vahlberg, T. J., Borghammer, P., Stefanova, N., Wenning, G. K., & Kaasinen, V. (2025) · Annals of Neurology · doi:10.1002/ana.27202 · Cited by 26
Carta, A. R., Boi, L., Pisanu, A., Palmas, M. F., Carboni, E., & Simone, A. D. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108685 · Cited by 27
Jimenez-Ferrer, I., Bäckström, F., Dueñas-Rey, A., Jewett, M., Boza-Serrano, A., Luk, K. C., Deierborg, T., & Swanberg, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.017 · Cited by 26
Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain
Streit, W. J., Xue, Q., Braak, H., & Tredici, K. D. (2013) · Glia · doi:10.1002/glia.22589 · Cited by 24
Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson’s Disease
Fischer, D. L., Gombash, S. E., Kemp, C. J., Manfredsson, F. P., Polinski, N. K., Duffy, M. F., & Sortwell, C. E. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_26 · Cited by 26
Ahn, T. B., Langston, J. W., Aachi, V. R., & Dickson, D. W. (2012) · Europe PMC (PubMed Central) · Cited by 24
Myeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 25
Blood brain barrier inflammation and potential therapeutic role of phytochemicals
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100177 · Cited by 22
Morissette, M., Bourque, M., Tremblay, M., & Paolo, T. D. (2022) · Cells · doi:10.3390/cells11040691 · Cited by 22
Stoll, A. C., Kemp, C. J., Patterson, J. R., Howe, J. W., Steece‐Collier, K., Luk, K. C., Sortwell, C. E., & Benskey, M. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106411 · Cited by 27
Remodeling microglia to a protective phenotype in Parkinson’s disease?
Awogbindin, I. O., Ishola, I. O., St‐Pierre, M., Carrier, M., Savage, J. C., Paolo, T. D., & Tremblay, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135164 · Cited by 21
Miller, C. R., Ealy, A., Gregory, A., Janarthanam, C., Albers, W. G., Richardson, G., Jin, H., Zenitsky, G. D., Anantharam, V., Kanthasamy, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115618 · Cited by 21
SNARE Proteins Mediate α-Synuclein Secretion via Multiple Vesicular Pathways
Zhao, X., Guan, Y., Liu, F., Yan, S., Wang, Y., Hu, M., Li, Y., Li, R., & Zhang, C. X. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02599-0 · Cited by 21
van den Berge, S. A., Kevenaar, J. T., Sluijs, J. A., & Hol, E. M. (2012) · Parkinson s Disease · doi:10.1155/2012/420957 · Cited by 22
Pereira, C. P. M., Francis-Oliveira, J., Singulani, M. P., Ferreira, A. F. F., & Britto, L. R. G. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578019 · Cited by 22
Lipids Nutrients in Parkinson and Alzheimer’s Diseases: Cell Death and Cytoprotection
Nury, T., Lizard, G., & Véjux, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072501 · Cited by 21
Alpha-synuclein inclusion responsive microglia are resistant to CSF1R inhibition
Stoll, A. C., Kemp, C. J., Patterson, J. R., Kubik, M., Kuhn, N. C., Benskey, M. J., Duffy, M. F., Luk, K. C., & Sortwell, C. E. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03108-5 · Cited by 23
Xu, J., He, X., Li, L., Zhang, L., Li, M., Mu, Y., Yang, X., Li, S., Feng, Y., Zuo, Z., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00912-5 · Cited by 22
Okuda, S., Uemura, N., Sawamura, M., Taguchi, T., Ikuno, M., Uemura, M. T., Yamakado, H., & Takahashi, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01169-5 · Cited by 19
The Innate and Adaptive Immune Cells in Alzheimer’s and Parkinson’s Diseases
Huang, B., Zhenxin, Y., Chen, S., Tan, Z., Zong, Z., Zhang, H., & Xiong, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1315248 · Cited by 19
Harnessing the immune system for the treatment of Parkinson’s disease
Vedam‐Mai, V. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147308 · Cited by 20
Towards New Therapies for Parkinson's Disease
Finkelstein, D. I. (2011) · InTech eBooks · doi:10.5772/954 · Cited by 19
Pampuščenko, K., Jankevičiūtė, S., Morkūnienė, R., Šulskis, D., Smirnovas, V., Brown, G. C., & Borutaitė, V. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106817 · Cited by 20
Leukotriene Signaling as a Target in α-Synucleinopathies
Strempfl, K., Unger, M. S., Flunkert, S., Trost, A., Reitsamer, H. A., Hutter‐Paier, B., & Aigner, L. (2022) · Biomolecules · doi:10.3390/biom12030346 · Cited by 17
Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity
de Araújo, F. M., Frota, A. F., de Jesus, L. B., Cuenca‐Bermejo, L., Ferreira, K. M. S., dos Santos, C. C., Soares, É. N., Teles-Souza, J., Sanches, F. S., Costa, A. C. S., et al. (2023) · Neurotoxicity Research · doi:10.1007/s12640-022-00616-1 · Cited by 18
Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils
Patterson, J. R., Kochmanski, J. J., Stoll, A. C., Kubik, M., Kemp, C. J., Duffy, M. F., Thompson, K. E., Howe, J. W., Cole-Strauss, A., Kuhn, N. C., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-023-00620-y · Cited by 20
The role of T-lymphocytes in central nervous system diseases
Shen, J., Bian, N., Zhao, L., & Wei, J. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110904 · Cited by 20
TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson′s disease
Pant, H., & Binukumar, B. K. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.182681 · Cited by 17
Rabaneda‐Lombarte, N., Vidal-Taboada, J. M., Valente, T., Ezquerra, M., Fernández‐Santiago, R., Martı́, M. J., Compta, Y., Saura, J., & Solà, C. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00290-2 · Cited by 19
Ebert, S., Goos, M., Rollwagen, L., Baake, D., Zech, W., Esselmann, H., Wiltfang, J., Mollenhauer, B., Schliebs, R., Gerber, J., et al. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22270 · Cited by 17
Dopamine and Paraquat Enhance α-Synuclein-Induced Alterations in Membrane Conductance
Feng, L., & Maguire‐Zeiss, K. A. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9255-x · Cited by 19
Pathology of Parkinson's Disease
Halliday, G. M., & Murphy, K. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00009-x · Cited by 17
Clinical biomarkers for Lewy body diseases
Abdelmoaty, M. M., Lu, E., Kadry, R., Foster, E. G., Bhattarai, S., Mosley, R. L., & Gendelman, H. E. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01152-x · Cited by 17
Glial cell response to constant low light exposure in rat retina
Bruera, M. G., Benedetto, M. M., Guido, M. E., Degano, A. L., & Contin, M. A. (2022) · Visual Neuroscience · doi:10.1017/s0952523822000049 · Cited by 17
Araújo, F. M. D., Frota, A. F., de Jesus, L. B., Macedo, T. C., Cuenca‐Bermejo, L., Sanchez-Rodrigo, C., Ferreira, K. M. S., de Oliveira, J. V. R., Costa, M. D. F. D., Segura-Aguilar, J., et al. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01173-5 · Cited by 15
The Impact of microRNAs on Mitochondrial Function and Immunity: Relevance to Parkinson’s Disease
Guedes, B. F. S., Cardoso, S. M., & Esteves, A. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051349 · Cited by 16
Cristaldi, A., Conti, G. O., Pellitteri, R., Cognata, V. L., Copat, C., Pulvirenti, E., Grasso, A., Fiore, M., Cavallaro, S., Dell’Albani, P., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117575 · Cited by 16
Bathe, T., Hery, G. P., Villareal, J. A. B., Phillips, J. L., Cohen, E. M., Sharma, R. V., Tsering, W., & Prokop, S. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01770-7 · Cited by 15
Li, X., Li, Q., Zhang, Y., Bai, Y., Cao, Y., Yang, Y., Zang, L., Huang, M., & Sui, R. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103380 · Cited by 15
Xue, H.-X., Kong, H., Yu, Y.-G., Zhou, J., Chen, H.-Q., & Yin, Y. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000515 · Cited by 14
Zhao, J., Guo, X., Wang, B., Yang, Z., Huang, T., Guo, D., Zhang, M., & Song, J. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03063-6 · Cited by 14
Il-10 signaling reduces survival in mouse models of synucleinopathy
Cockey, S. G., McFarland, K. N., Koller, E. J., Brooks, M., Cruz, E. G. D. L., Cruz, P. E., Ceballos‐Diaz, C., Rosario, A. M., Levites, Y., Borchelt, D., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00169-8 · Cited by 14
Beyond Host Defense: Deregulation of Drosophila Immunity and Age-Dependent Neurodegeneration
Arora, S., & Ligoxygakis, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01574 · Cited by 14
The Role of Free Radicals in the Nervous System
Friedman, J. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-514-9_1 · Cited by 14
Guo, X., Wei, R., Yin, X., & Yang, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528538 · Cited by 13
Prasad, K., de Vries, E. F. J., van der Meiden, E., Moraga‐Amaro, R., Vazquez-Matias, D. A., Barazzuol, L., Dierckx, R., & van Waarde, A. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109862 · Cited by 13
Microglia in Neurodegenerative Diseases
Awogbindin, I. O., Wanklin, M., Verkhratsky, A., & Tremblay, M. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_27 · Cited by 14
Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson’s Disease Models
Tada, S., Choudhury, M. E., Kubo, M., Ando, R., Tanaka, J., & Nagai, M. (2022) · Brain Sciences · doi:10.3390/brainsci12020268 · Cited by 12
Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragments
Rabenstein, M., Agbo, D. B., Wolf, E., Dams, J., Nicolai, M., Roeder, A., Bacher, M., Dodel, R. C., & Noelker, C. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.004 · Cited by 13
Berger, C., Welsh, N. C., Sepulveda‐Rodriguez, A., Vicini, S., & Maguire‐Zeiss, K. A. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13711 · Cited by 12
Microglia at the Centre of Brain Research: Accomplishments and Challenges for the Future
Soares, N. L., & Vieira, H. L. A. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03456-1 · Cited by 14
Stokholm, K., Thomsen, M. B., Phan, J.-A., Møller, L. K., Bay-Richter, C., Christiansen, S. H., Woldbye, D. P. D., Romero‐Ramos, M., & Landau, A. M. (2021) · Biomedicines · doi:10.3390/biomedicines9121876 · Cited by 13
Sex-dimorphic neuroprotective effect of CD163 in an α-synuclein mouse model of Parkinson’s disease
Ferreira, S. A., Li, C., Klæstrup, I. H., Vitic, Z., Rasmussen, R. K., Kirkegaard, A., Toft, G. U., Betzer, C., Svendsen, P., Jensen, P. H., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00606-w · Cited by 12
Ma, W., Geng, Y., Liu, Y., Pan, H., Wang, Q., Zhang, Y., & Wang, L. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1345918 · Cited by 11
Ovlyakulov, B., Hu, B., Kan, H.-Y., Guo, Q., Li, X., Fan, H.-H., Wu, H., Wang, J., Zhang, X., & Zhu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112715 · Cited by 11
Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease
Urmeneta-Ortíz, M. F., Tejeda-Martínez, A. R., González‐Reynoso, O., & Flores-Soto, M. E. (2024) · Parkinson s Disease · doi:10.1155/2024/5519396 · Cited by 14
Saad, H. M., Salem, E. A., & Elsayed, A. E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04818-4 · Cited by 11
Zhou, L., Li, Y., Wang, M., Han, W., Chen, Q., Zhang, J., Sun, B., & Fan, Y. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.05.013 · Cited by 10
García‐Yagüe, Á. J., Esteras, N., Dinkova‐Kostova, A. T., Rojo, A. I., Shiels, P. G., Dinnyés, A., Tamas, V., van Goor, H., & Lastres‐Becker, I. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.01.023 · Cited by 12
Anwar, M. M., Pérez‐Martínez, L., & Pedraza‐Alva, G. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2358446 · Cited by 11
Kuhlman, G. D., Auinger, P., Duff-Canning, S. J., Lang, A. E., Tanner, C. M., & Marras, C. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120822 · Cited by 9
Altered Synaptic Plasticity: Plausible Mechanisms Associated With Viral Infections
Saini, V., Rani, A., Kumar, A., Jha, K., Karnati, S., & Jha, H. C. (2023) · Future Virology · doi:10.2217/fvl-2023-0105 · Cited by 7
Role of NLRP3 Inflammasomes in Neurodegenerative Diseases
Demirtaş, N., Mazlumoğlu, B. Ş., & Palabıyık, Ş. S. (2023) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2023.23349 · Cited by 8
Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model
Iba, M., Lee, Y., Horan-Portelance, L., Chang, K., Szabo, M. P., Rissman, R. A., You, S., Masliah, E., & Kim, C. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.09.016 · Cited by 9
Fiandaca, M. S., & Federoff, H. J. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.014 · Cited by 8
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00683-8 · Cited by 8
From onset to advancement: the temporal spectrum of α-synuclein in synucleinopathies
Wiseman, J. A., Reddy, K., & Dieriks, B. V. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102640 · Cited by 9
Metadata
- Authors
- Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Graeber, Manuel B
- ORCID
- Dexter, David T
- Venue
- Journal of Neuroinflammation
- Published
- 2005-06-03
- Volume
- 2
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC1177985
- OpenAlex
- W1822935226
- Cited by
- 414
- References
- 34
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 44 · 2023: 24 · 2022: 25 · 2021: 38 · 2020: 44 · 2019: 18 · 2018: 22 · 2017: 15 · 2016: 13 · 2015: 19 · 2014: 18 · 2013: 19 · 2012: 11
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Parkinson's UK (G-4028)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, microglial activation, substantia nigra, MHC class II expression, CD68, microglial phagocytosis, neuroinflammation, disease duration, neuronal loss, postmortem brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
